Key factors
sym | ONTX |
exch | US |
MCap | 20.90M |
Beta | 1.349 |
EPS | -0.96 |
Div date | 0000-00-00 |
Yesterday
sym | ONTX |
exch | US |
close | 7.93 |
50 Day MA | 0.815 |
200 Day MA | 0.783 |
52 Week High | 7.97 |
52 Week Low | 0.550 |
Target Price | 8.33 |
Market Cap Mln | 20.90 |
Share statistics
Shares Outstanding | 21.00M |
Shares Float | 20.83M |
Percent Institutions | 7.949 |
PercentInsiders | 0.779 |
SharesShort | 20695 |
Short Ratio | 0.19 |
Shares Short Prior Month | 50303 |
Short Percent | 0.100 |
Income
Revenue TTM | 226.0K |
Revenue Per Share TTM | 0.011 |
Gross Profit TTM | 226.0K |
EBITDA | -21.5M |
Diluted Eps TTM | -0.96 |
earning
Operating Margin TTM | -89.2 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Current Year | -0.88 |
EPS Estimate Next Quarter | -0.25 |
EPS Estimate Next Year | -0.86 |
Earnings Share | -0.96 |
Dividend
Dividend Date | 2018-09-26 |
Last Split Date | 2021-05-21 |
Last Split Factor | 1:15 |
business
Enterprise Value Ebitda | 0.048 |
Enterprise Value Revenue | 150.47 |
Book Value /share | 0.691 |
Price Book MRQ | 1.858 |
Price Sales TTM | 92.49 |
ReturnOnAssetsTTM | -0.38 |
ReturnOnEquityTTM | -0.84 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US68232V8019 |
CIK | 1130598 |
Code | ONTX |
CUSIP | 68232V405 |
Employer Id Number | 22-3627252 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic Primary |
info
Fiscal Year End | December |
Full Time Employees | 16.0 |
IPODate | 2013-07-25 |
International Domestic | International Domestic |
MostRecent Quarter | 2024-03-31 |
Contact
Name | Onconova Therapeutics Inc |
Address | 12 Penns Trail, Newtown, PA, United States, 18940 |
Country Name | USA |
Phone | 267 759 3680 |
Web URL | https://www.onconova.com |
Logo URL | /img/logos/US/ONTX.png |
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.